Abstract
In Singapore astrocytic tumours occur in only 25% of patients with primary brain tumours compared to 40–60% in other series. Glioblastoma multiforme arises either de novo as a primary glioblastomas associated with epidermal growth factor receptor (EGFR) and mdm2 over-expression or as a secondary glioblastomas, through malignant progression from low-grade astrocytomas, associated with p53 mutations and PDGFR-α over-expression. Using immunohistochemical methods and DNA sequencing, we studied our population of glioblastomas for over-expression of EGFR, mdm2, p53, and PDGFR-α as well directly for mutations of the p53 gene. While levels of over-expression of EGFR and mdm2 were consistent with levels expected for primary glioblastomas, levels of p53 and PDGFR-α were consistent with levels documented for secondary glioblastomas. Notably 96% of the samples over-expressed p53 as detected with monoclonal antibody pAb 240. Of the 39 samples available for DNA sequencing 18% (7/39) had p53 mutations, including three mutations previously undocumented in glioblastomas. These results provide strong evidence that glioblastomas in Asian patients do not conform to currently accepted models of glioblastoma development, and that clinically defined glioblastomas in these patients show genetic changes consistent with both ‘primary’ and 'secondary’ glioblastomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zulch KJ: Brain Tumors. Their Biology and Pathology. 3rd edn., Springer Verlag, Berlin Heidelberg, 1986
Das A, Chapman CAT, Yap WM: Histological subtypes of symptomatic central nervous system tumours in Singapore. J Neurol Neurosurg Psych 68: 370–374, 2000
Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217–223, 1996
Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplifi-cation and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180–185, 1997
Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN(MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684–689, 1998
Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl) 94: 303–309, 1997
Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK: Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and Genetics of Tumors of the Nervous System. International Agency for Research on Cancer, Lyon, 1997, pp 16–24
Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncol 1: 44–51, 1999
Hsu SM, Raine L, Fanger H: Use of avidin-biotinperoxidase complex (ABC) in immnoperoxidase techniques. J Histochem Cytochem 29: 577–580, 1981
Lau KE: Singapore census of population 1990. Statistical Release 1: Demographics and Characteristics. Department of Statistics, Singapore 1992
Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC: Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24: 141–146, 1996
Beroud C, Soussi T: p53 gene mutation: software and database. Nucleic Acids Res 26: 200–204, 1998
Ohgaki H, Schäuble B, zur Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchows Arch 427: 113–118, 1995
Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 513–530, 1997
Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 313: 144–147, 1985
Ekstrand AJ, Sugawa N, James CD, Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of N-and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309–4313, 1992
Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965–2969, 1992
Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplifi-cation and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180–185, 1997
Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodeman HP, Bamberg M: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neuro-Oncol 49: 197–203, 2000
Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A, Nister M: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor receptor expression in human malignant gliomas. Cancer Res 56: 164–171, 1996
Ng HK, Lo SY, Huang DP, Poon WS: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26: 1–5, 1994
Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11–21, 1994
Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC: A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229–235, 1993
von Deimling A, von Ammon K, Schoenfeld DA, Wiestler OD, Seizinger BR, Louis DN: Subsets of 125 glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19–26, 1993
Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz A, Takahashi M, Wrensch M: Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res 61: 3949–3954, 2001
Cheng Y, Ng HK, Ding M, Zhang SF, Pang JCS, Lo KW: Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 58: 120–128, 1999
Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AS, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31–38, 1993
Elledge RM, Clark GM, Chamness GC, Osborne CK: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86: 705–712, 1994
Shiao YH, Chen VW, Wu XC, Scheer WD, Lehmann HP, Malcom GT, Boudreau DA, Ruiz B, Correa P: Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo 10: 169–173, 1996
Chia SJ, Tang WY, Elnatan J, Yap WM, Goh HS, Smith DR: Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer 83: 761–768, 2000
Watanabe M, Fukutome K, Shiraishi T, Murata M, Kawamura J, Shimazaki J, Kotake T, Yatani R: Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis 18: 1355–1358, 1997